Xeloda

In the US, Xeloda (capecitabine systemic) is a member of the drug class antimetabolites and is used to treat Breast Cancer, Breast Cancer - Metastatic, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma and Stomach Cancer.

US matches:

• Xeloda

UK matches:

• Xeloda (SPC)

Ingredient matches for Xeloda

Capecitabine

Capecitabine is reported as an ingredient of Xeloda in the following countries:

• Algeria


• Argentina


• Armenia


• Australia


• Austria


• Azerbaijan


• Bahrain


• Bangladesh


• Belarus


• Belgium


• Bosnia & Herzegowina


• Brazil


• Canada


• Chile


• China


• Colombia


• Croatia (Hrvatska)


• Cyprus


• Czech Republic


• Denmark


• Ecuador


• Egypt


• Estonia


• Finland


• France


• Georgia


• Germany


• Greece


• Hong Kong


• Hungary


• Iceland


• India


• Indonesia


• Iran


• Iraq


• Ireland


• Israel


• Italy


• Jamaica


• Japan


• Jordan


• Kazakhstan


• Kuwait


• Lebanon


• Lithuania


• Luxembourg


• Malaysia


• Mexico


• Morocco


• Netherlands


• New Zealand


• Norway


• Oman


• Pakistan


• Paraguay


• Peru


• Philippines


• Poland


• Portugal


• Qatar


• Romania


• Russian Federation


• Saudi Arabia


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• South Korea


• Spain


• Sri Lanka


• Sweden


• Switzerland


• Syria


• Taiwan


• Thailand


• Trinidad & Tobago


• Turkey


• Ukraine


• United Arab Emirates


• United Kingdom


• United States


• Uruguay


• Uzbekistan


• Venezuela


• Vietnam


• Yemen

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.